Login to Your Account



G-Zero Cedes to Start-up G1 in Small-Molecule Inhibitors

By Marie Powers
Staff Writer

Thursday, November 15, 2012
Based on discoveries licensed from the University of North Carolina at Chapel Hill, privately held G1 Therapeutics Inc. is trained on the discovery and development of small molecules targeting proteins associated with cell proliferation and growth in cancer therapy and biodefense.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription